Swiss regulator approves Pfizer/BioNTech booster for 16 and up
Swissmedic has approved the extension of Covid-19 boosters for the Pfizer/BioNTech vaccine to all people aged 16 and over. This now "clears the way" for wider use of the booster vaccination, it said.
This content was published on
3 minutes
Keystone-SDA/jdp
Русский
ru
Вакцина от Pfizer/BioNTech одобрена для ревакцинации в Швейцарии
On Tuesday, the Swiss Agency for Therapeutic Products said that it was “adapting the product information” for the Pfizer/BioNTech so that a booster can be administered to people 16 years and up. In all cases, the third dose must be administered at least six months after the second dose.
Swissmedic reached the decision based on, among other things, a study involving 10,000 participants aged 16 to 87 years. The interim results of this study did not reveal any evidence of “new risk aspects” with the third vaccine dose, Swissmedic said.
Swissmedic “continues to monitor very closely the benefits and risks of the vaccine” for preventing Covid-19. The extension of boosters doesn’t apply to the Moderna vaccine.
The Federal Commission for Vaccination is now specifying detailed vaccination recommendations for the extension.
Booster doses of both the Pfizer/BioNTech and Moderna vaccines are currently being administered to specific groups, namely people over 65 and “people with a weakened immune system” from the age of 12. This followed Swissmedic’s approval of boosters at the end of October. A booster campaign for the rest of the population is expected to start soon.
More
More
Many cantons are unready for big Covid-19 booster campaign, says paper
This content was published on
The authorities are unprepared for a Covid-19 booster campaign for the under-65s, reports the SonntagsZeitung newspaper.
The Swiss government also announced on Tuesday that it has reserved around 8,000 packages of the antiviral drug Molnupiravir to treat Covid-19. A clinical trial has demonstrated efficacy in non-hospitalised Covid-19 patients at high risk of severe disease progression, said the Swiss National Scientific Taskforce.
With this deal, the government saidExternal link the country has access to another “promising” Covid-19 drug, in addition to casirivimab/imdevimab (developed by Roche and Regeneron) and sotrovimab (sold by GSK). In contrast to these monoclonal antibodies, molnupiravir is an antiviral treatment and can be administered orally. According to the Federal Office of Public Health, the government will cover the cost of treatment in the outpatient setting until it is reimbursed by mandatory health insurance.
Molnupiravir is expected to be available by January 2022 at the latest but it has not been approved in Switzerland. However, it can already be used to treat Covid-19 patients during the ongoing approval process after “an adaptation of Covid-19 Regulation 3, which has yet to take place,” the statement added.
The contract, the amount of which is confidential, was signed with the company MSD Merck Sharp & Dohme Switzerland.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
Swiss study: insects mainly migrate at midday and dusk
This content was published on
A study led by the Swiss Ornithological Institute in canton Lucerne is helping to better understand the movement patterns of migratory insects.
Red Cross: 22 staff killed in Middle East since October
This content was published on
The Red Cross and Red Crescent network in Gaza and Israel has lost 22 staff members since last October, the Swiss Red Cross (SRC) said on Wednesday.
This content was published on
Although it has only been in operation since 2000, the Institute of Research in Biomedicine (IRB) has already become a centre of international importance in the field of biomedical research. It has over 300 publications to its credit in academic journals, including Science and Nature. A visitor arriving at the institute for the first…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.